Defunct Company
Total Trials
4
As Lead Sponsor
2
As Collaborator
Total Enrollment
230
NCT00114959
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Phase: Phase 2
Role: Lead Sponsor
Start: Oct 31, 2005
Completion: Mar 31, 2009
NCT00375219
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Role: Collaborator
Start: Sep 20, 2006
Completion: Jun 28, 2013
NCT00462943
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
Start: Mar 7, 2007
Completion: Jun 27, 2013
NCT00675350
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Phase: Phase 1
Start: Apr 30, 2008
Completion: Jan 31, 2009